AU2007230991A1 - Compounds and methods for treatment of disorders associated with ER stress - Google Patents

Compounds and methods for treatment of disorders associated with ER stress Download PDF

Info

Publication number
AU2007230991A1
AU2007230991A1 AU2007230991A AU2007230991A AU2007230991A1 AU 2007230991 A1 AU2007230991 A1 AU 2007230991A1 AU 2007230991 A AU2007230991 A AU 2007230991A AU 2007230991 A AU2007230991 A AU 2007230991A AU 2007230991 A1 AU2007230991 A1 AU 2007230991A1
Authority
AU
Australia
Prior art keywords
independently
lower alkyl
substituted
occurrence
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007230991A
Other languages
English (en)
Inventor
Nicholas D.P. Cosford
Teoman Uysal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SYNDEXA PHARMACEUTICALS CORP
Original Assignee
SYNDEXA PHARMACEUTICALS CORP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SYNDEXA PHARMACEUTICALS CORP filed Critical SYNDEXA PHARMACEUTICALS CORP
Publication of AU2007230991A1 publication Critical patent/AU2007230991A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2007230991A 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with ER stress Abandoned AU2007230991A1 (en)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US78518206P 2006-03-22 2006-03-22
US78533506P 2006-03-22 2006-03-22
US78503406P 2006-03-22 2006-03-22
US78500706P 2006-03-22 2006-03-22
US78533806P 2006-03-22 2006-03-22
US78523506P 2006-03-22 2006-03-22
US78503506P 2006-03-22 2006-03-22
US78518506P 2006-03-22 2006-03-22
US78532806P 2006-03-22 2006-03-22
US78515406P 2006-03-22 2006-03-22
US60/785,335 2006-03-22
US60/785,235 2006-03-22
US60/785,328 2006-03-22
US60/785,034 2006-03-22
US60/785,007 2006-03-22
US60/785,035 2006-03-22
US60/785,154 2006-03-22
US60/785,182 2006-03-22
US60/785,185 2006-03-22
US60/785,338 2006-03-22
PCT/US2007/007228 WO2007111994A2 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with er stress

Publications (1)

Publication Number Publication Date
AU2007230991A1 true AU2007230991A1 (en) 2007-10-04

Family

ID=38541676

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007230991A Abandoned AU2007230991A1 (en) 2006-03-22 2007-03-22 Compounds and methods for treatment of disorders associated with ER stress

Country Status (6)

Country Link
US (1) US20090131384A1 (enExample)
EP (1) EP2001897A2 (enExample)
JP (1) JP2009530399A (enExample)
AU (1) AU2007230991A1 (enExample)
CA (1) CA2681639A1 (enExample)
WO (1) WO2007111994A2 (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518278B1 (pt) 2004-10-26 2018-04-24 Dolby Laboratories Licensing Corporation Método e aparelho para controlar uma característica de sonoridade particular de um sinal de áudio
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20110092554A1 (en) * 2007-11-19 2011-04-21 Richard Chesworth 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
BRPI0819847B1 (pt) 2007-11-27 2022-01-11 Ardea Biosciences, Inc Compostos e composições
WO2009086277A1 (en) 2007-12-20 2009-07-09 Envivo Pharmaceuticals, Inc. Tetrasubstituted benzenes
US8242154B2 (en) 2008-09-04 2012-08-14 Ardea Biosciences, Inc. Compounds, compositions and methods of using same for modulating uric acid levels
EP2367839A4 (en) * 2008-11-03 2012-07-04 Univ Tufts METHOD AND COMPOSITIONS FOR INHIBITING CLOSTRIDIUM DIFFICILE SPORTS NUTRITION AND GROWTH
EP2255813A1 (en) * 2009-05-29 2010-12-01 The Royal College of Surgeons in Ireland Derivatives of ursodeoxycholic acid for the treatment of diarrhoea
PL2519100T3 (pl) 2009-12-29 2017-09-29 Mapi Pharma Limited Związki pośrednie i sposoby wytwarzania tapentadolu i pokrewnych związków
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
RU2569678C2 (ru) 2010-04-22 2015-11-27 Вертекс Фармасьютикалз Инкорпорейтед Способ получения циклоалкилкарбоксамидо-индольных соединений
AR081930A1 (es) 2010-06-16 2012-10-31 Ardea Biosciences Inc Compuestos de tioacetato
TWI499412B (zh) 2010-06-16 2015-09-11 亞德生化公司 苯基硫乙酸酯組合物及其使用方法
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ES2704233T3 (es) 2011-11-03 2019-03-15 Ardea Biosciences Inc Compuesto de piridina 3,4-di-sustituido, procedimientos de uso y composiciones que comprenden el mismo
EP2844257A4 (en) 2012-05-01 2016-06-01 Catabasis Pharmaceuticals Inc Fatty Acid Conjugates from Statin and FXR Agonists; COMPOSITIONS AND METHODS OF USE
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
CN111529535A (zh) 2012-09-27 2020-08-14 儿童医学中心公司 用于治疗肥胖症的化合物和其使用方法
ES2736599T3 (es) 2013-03-14 2020-01-03 Univ Macau Nuevos compuestos naturales antineurodegenerativos aislados a partir de Alpiniae oxyphyllae fructus y síntesis total de los mismos
PL3925607T5 (pl) 2014-04-15 2026-06-01 Vertex Pharmaceuticals Incorporated Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa
BR112017009657A2 (pt) * 2014-11-06 2018-01-23 Enanta Pharmaceuticals, Inc análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
RU2017121457A (ru) 2014-11-26 2018-12-26 Энанта Фармасьютикалс, Инк. Аналоги желчной кислоты в качестве агонистов fxr/tgr5 и способы их применения
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2016086115A1 (en) 2014-11-26 2016-06-02 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
RU2712099C2 (ru) 2015-03-31 2020-01-24 Энанта Фармасьютикалс, Инк. Производные желчных кислот в качестве агонистов fxr/tgr5 и способы их применения
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
WO2017147174A1 (en) 2016-02-23 2017-08-31 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
DE102017005884A1 (de) * 2016-07-07 2018-01-11 Merck Patent Gmbh Elektronisches Schaltelement
AU2017368069B2 (en) 2016-11-29 2021-07-08 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
MX388300B (es) 2017-04-07 2025-03-19 Enanta Pharm Inc Proceso para la preparación de derivados de ácidos biliares de sulfonil carbamato
DE102018004733B4 (de) * 2018-06-14 2026-06-11 Merck Patent Gmbh Verfahren zur Herstellung eines elektronischen Bauteils enthaltend eine selbstorganisierte Monolage
CN116925168A (zh) 2019-08-23 2023-10-24 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
JP2024529444A (ja) * 2021-07-26 2024-08-06 シャペロン インク． ＴＮＦ－α生成及び炎症複合体活性抑制新規化合物及びその製造方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1152801B (it) * 1982-08-17 1987-01-14 Proter Spa Composti steroidei ad attivita' coleretica, processo per la loro preparazione e composizioni terapeutiche che li contengono come principio attivo
JPS60161996A (ja) * 1984-02-01 1985-08-23 Eisai Co Ltd ケノデオキシコ−ル酸またはウルソデオキシコ−ル酸誘導体およびその製造法ならびにそれを含有する医薬
JP2616845B2 (ja) * 1991-02-21 1997-06-04 清水化学株式会社 システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
JPH0959162A (ja) * 1995-08-28 1997-03-04 Makoto Takahashi 胆石溶解剤
WO2001076531A2 (en) * 2000-04-07 2001-10-18 University Of Maryland, Baltimore Bile acid containing prodrugs with enhanced bioavailability
AU2002230398A1 (en) * 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs

Also Published As

Publication number Publication date
JP2009530399A (ja) 2009-08-27
US20090131384A1 (en) 2009-05-21
WO2007111994A2 (en) 2007-10-04
CA2681639A1 (en) 2007-10-04
EP2001897A2 (en) 2008-12-17
WO2007111994A3 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
CA2681639A1 (en) Compounds and methods for treatment of disorders associated with er stress
AU2007319848B2 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
DK2041068T3 (en) POSITIVELY CHARGED, WATER SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION SPEED
TW201711706A (zh) 標靶藥物遞送及提升ｓｉＲＮＡ活性用脂溶性維生素化合物
US20150196509A1 (en) Compositions Comprising Statins, Biguanides and Further Agents for Reducing Cardiometabolic Risk
JP6608404B2 (ja) 非アルコール性脂肪性肝疾患及び非アルコール性脂肪性肝炎の処置方法
AU2013290100A1 (en) Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
TW201805283A (zh) sGC刺激劑之固體形式
EP0036637A1 (en) Use of 3,3'-azo-bis-(6-hydroxy benzoic acid) as a drug and pharmaceutical compositions containing the same
JP5341521B2 (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
US20250313522A1 (en) Phenoxy carboxylic acid compounds and medical uses thereof
CN118620018B (zh) 一种侧链含噁二唑结构的甾体类fxr激动剂及其制备方法和应用
JP2024041865A (ja) パ－キンソン病治療用の新規高透過薬物及びその組成物
US20220348601A1 (en) Ruthenium arene schiff-base complexes and uses thereof
WO2023160702A1 (zh) 氨基脂质化合物、其制备方法、组合物和应用
CN104797568A (zh) 用于治疗神经障碍的组合物和方法
CN102432607A (zh) 一种吡嗪异喹啉衍生物在制备治疗血吸虫药物中的应用
CN102532114A (zh) 烟酸衍生物,其制备方法及其药物组合物
CN113402444A (zh) 一种咔唑类化合物及其在制备治疗脂肪肝及2型糖尿病等代谢相关疾病药物中的应用
WO2013070911A1 (en) Compounds and methods for treating cystic fibrosis
US20260001833A1 (en) Compounds, compositions, and methods for reducing production of trimethylamine
WO2012049566A1 (en) Combination therapy for use in treating diabetes
WO2014151697A1 (en) Therapeutic uses for geranylgeranyl acetone and derivatives thereof
WO2025096684A1 (en) Err modulators
CN116354913A (zh) 抗肾纤维化天然产物Commiphorane C异构体其制法与用途

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application